New insider activity at Tyra Bioscience ( (TYRA) ) has taken place on February 8, 2025.
Director Nina Kjellson recently sold 5,401 shares of Tyra Bioscience stock, totaling a transaction value of $74,317.
Recent Updates on TYRA stock
Tyra Biosciences recently announced significant developments, including changes in its Board of Directors with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo, who is anticipated to enhance the company’s strategic direction due to her extensive experience in the biopharmaceutical industry. Additionally, the U.S. FDA has cleared Tyra Biosciences’ Investigational New Drug application for TYRA-300, enabling the commencement of a Phase 2 clinical trial for non-muscle invasive bladder cancer. This trial will be led by Dr. Erik Goluboff, a seasoned expert in the field. These developments, along with market factors, have led to adjustments in the stock’s price targets by various analysts, reflecting the impact of regulatory progress and leadership changes on the company’s future prospects.
More about Tyra Bioscience
YTD Price Performance: -8.73%
Average Trading Volume: 242,632
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $666.4M